Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1126 AL 1140

Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, Kollmorgen G, Bayfield A, Wild N, Hoffman J, Ceniceros R, Dolton M, Bohórquez SMS, Hoogenraad CC, Wildsmith KR, Teng E, Monteiro C, Anania V, Yeh FL.

Alzheimers Dement. 2024 Dec;20(12):8855-8866. doi: 10.1002/alz.14346. Epub 2024 Nov 8.

Public-Private Partnerships for Neuropsychiatric Drug Development: A Perspective

Potter WZ.

Adv Neurobiol. 2024;40:67-85. doi: 10.1007/978-3-031-69491-2_3.

The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics

Dong Y, Song X, Wang X, Wang S, He Z.

CNS Neurosci Ther. 2024 Nov;30(11):e70060. doi: 10.1111/cns.70060.

Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications

Jamerlan AM, An SSA, Hulme JP.

J Neurol Sci. 2024 Dec 15;467:123325. doi: 10.1016/j.jns.2024.123325. Epub 2024 Nov 22.

Unlocking early detection of Alzheimer's disease: The emerging role of nanomaterial-based optical sensors

Chen CH, Liang HH, Wang CC, Yang YT, Lin YH, Chen YL.

J Food Drug Anal. 2024 Sep 13;32(3):296-324. doi: 10.38212/2224-6614.3520.

Medication Exposure and Risk of Dementia and Alzheimer's Disease

Sharma N, An SSA, Kim SY.

Int J Mol Sci. 2024 Nov 29;25(23):12850. doi: 10.3390/ijms252312850.

Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer's Disease: A Review and Meta-Analysis

Lombardi G, Pancani S, Manca R, Mitolo M, Baiardi S, Massa F, Coppola L, Franzese M, Nicolai E, Guerini FR, Mancuso R, Agliardi C, Agostini S, Pardini M, Virgili G, Sorbi S, Parchi P, Nacmias B, Venneri A.

Int J Mol Sci. 2024 Nov 30;25(23):12916. doi: 10.3390/ijms252312916.

The Implication of Glial Metabotropic Glutamate Receptors in Alzheimer's Disease

de Lima IBQ, Ribeiro FM.

Curr Neuropharmacol. 2023;21(2):164-182. doi: 10.2174/1570159X20666211223140303.

The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease

Bland AR, Ashton JC, Kamal MA, Sahebkar A.

CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.

Impact of the Cannabinoid System in Alzheimer's Disease

Li S, Huang Y, Yu L, Ji X, Wu J.

Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.

Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease

Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.

Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.

Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease

Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.

CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease

Martins GL, Ferreira CN, Palotás A, Rocha NP, Reis HJ.

Curr Neuropharmacol. 2023;21(2):202-212. doi: 10.2174/1570159X20666220327215245.

Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease

Unnisa A, Greig NH, Kamal MA.

Curr Med Chem. 2023;30(3):255-270. doi: 10.2174/0929867329666220328125206.

Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review

Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.

CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias